Japan approves Effexor SR as first treatment for generalized anxiety disorder (GAD) in adults.

Japan's Ministry of Health has approved Effexor SR (venlafaxine hydrochloride) capsules for treating adults with generalized anxiety disorder (GAD), making it the first and only approved treatment for GAD in Japan. This approval addresses a significant unmet medical need, as GAD affects a notable portion of the population and impairs quality of life. The decision is based on successful clinical trials demonstrating Effexor's efficacy and safety. Viatris plans to leverage its expertise to bring this new treatment to patients in Japan, expanding access to care for this common mental health condition.